

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2018

Sr. No	Particulars	Standalone						Consolidated						YTD 31.03.2018
		Quarter ended		Nine months ended		Year ended		Quarter ended		Nine months ended		Year ended		
		31.12.2018	30.09.2018	31.12.2017	31.12.2017	31.03.2018	31.12.2017	31.12.2018	31.12.2017	31.12.2018	31.12.2017	31.12.2018	31.03.2018	
I	Revenue from Operations	9,563.20	11,997.15	7,359.28	32,044.70	21,497.55	29,829.38	22,843.01	19,592.25	65,419.84	64,803.96	37,251.55	44,262.45	81,514.00
II	Other Income	-435.12	2,400.58	1,19.90	3,279.48	665.65	1,099.50	2,487.49	233.52	3,484.01	2,099.49	1,966.17	687.33	2,653.50
III	Total Income (I+II)	9,128.08	14,397.73	7,479.18	35,324.18	22,163.20	30,928.88	25,330.50	19,825.77	68,903.85	66,903.45	39,217.72	44,949.78	84,167.50
IV	Expenses	3,218.02	3,296.52	4,158.88	11,537.79	10,970.00	14,989.90	4,545.98	8,388.31	15,032.73	30,779.34	19,207.38	19,415.24	38,622.62
a.	Cost of Materials consumed	1,874.45	2,748.55	5,146.46	5,146.46	-	-	10,730.42	108.54	29,074.05	285.53	546.98	-	546.98
b.	Purchase of Stock-in-Trade	-442.12	633.96	-559.22	-11.68	-10.93	-409.14	-112.73	-584.74	-167.26	442.03	-331.39	274.50	-56.89
c.	Changes in inventories of work in process, finished goods and stock in trade	-	-	3.41	-	50.79	40.15	-	3.41	-	65.61	49.59	-	49.59
d.	Excise Duty	881.43	807.48	702.03	2,500.04	1,944.85	2,629.44	1,016.12	1,772.84	3,122.46	5,214.64	3,386.96	3,536.19	6,923.15
e.	Employee Benefit Expense	67.47	91.82	153.93	250.44	537.09	695.14	126.87	472.10	348.90	1,735.60	860.17	1,419.95	2,280.12
f.	Finance Costs	133.93	150.85	216.84	430.06	421.17	567.16	219.39	233.86	673.93	1,650.86	907.08	1,231.21	2,138.29
g.	Depreciation and Amortisation Expense	1,567.50	1,748.37	1,087.02	4,955.73	2,532.11	3,732.51	1,865.18	2,028.19	5,787.52	12,056.47	4,771.63	10,942.95	15,714.58
h.	Other Expenses	7,300.68	9,477.55	5,762.89	24,808.84	16,435.08	22,245.16	18,005.25	19,051.00	53,872.33	52,230.08	29,398.41	36,820.03	66,218.44
V	Total Expenses	1,827.40	4,920.18	1,716.29	10,515.34	5,718.12	8,683.72	3,648.03	6,279.50	15,031.52	14,673.37	8,129.75	8,129.75	17,949.06
VI	Profit / (Loss) before exceptional items and tax (III-IV)	1,827.40	4,920.18	1,716.29	10,515.34	5,718.12	8,683.72	3,648.03	6,279.50	15,031.52	14,673.37	8,129.75	8,129.75	17,949.06
VII	Exceptional Items	-	-	-	-	-	-	-	-	-	-	-3,419.88	-	-3,419.88
VIII	Profit / (Loss) before Tax (V-VI)	1,827.40	4,920.18	1,716.29	10,515.34	5,718.12	8,683.72	3,648.03	6,279.50	15,031.52	14,673.37	6,399.43	8,129.75	14,529.18
IX	Tax Expense	648.67	1,641.87	539.88	3,442.73	1,744.86	3,020.38	1,022.11	1,941.42	4,259.61	4,238.07	3,290.99	2,435.75	5,726.74
X	Net Profit / (Loss) for the period	8.66	173.20	84.15	92.73	251.06	-38.12	-96.95	46.46	-15.64	126.13	-63.29	-63.29	-63.29
	Other Comprehensive Income	1,170.07	3,405.11	1,040.21	6,979.88	3,670.15	5,701.46	2,722.87	4,466.53	10,787.55	10,238.27	3,172.75	5,693.99	8,866.49
	Profit/(Loss) from continuing operations(after tax) (VII-VIII)	1,170.07	3,405.11	1,040.21	6,979.88	3,670.15	5,701.46	2,722.87	4,466.53	10,787.55	10,238.27	3,172.75	5,693.99	8,866.49
	Profit/(Loss) from discontinuing operations(after tax)	-	-	-	-	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income	1,170.07	3,405.11	1,040.21	6,979.88	3,670.15	5,701.46	2,722.87	4,466.53	10,787.55	10,238.27	3,172.75	5,693.99	8,866.49
	Items that will not be reclassified to profit & loss	2.49	2.52	-3.12	7.50	-9.35	29.13	2.50	2.50	7.50	-11.19	27.30	-	27.30
	Items that will be reclassified to profit & loss	-1.01	-0.85	1.08	-2.62	3.24	-10.08	-1.01	-0.85	-2.62	3.24	-10.08	-	-10.08
	Deferred tax on remeasurement of defined benefit liabilities/(assets)	-	-	-	-	-	-	-432.83	1,014.76	-307.95	-173.57	-70.52	-181.18	-251.69
	Change in revaluation Surplus	-	-	-	-	-	-	121.73	-296.30	92.39	67.99	70.86	30.84	30.84
	Deferred tax on change in revaluation surplus	-	-	-	-	-	-	-	-	-	-	-	-	-
	Items that will be reclassified to profit & loss	-	-	-	-	-	-	-	-	-	-	-	-	-
	Exchange differences in translating the financial statements of foreign operations	-	-	-	-	-	-	-	-	-	-	-	-	-
	Others	-	-	-	-	-	-	-	-	-	-	-	-	-
	Deferred tax relating to items that will be reclassified to profit	-	-	-	-	-	-	-	-	-	-	-	-	-
XI	Total Comprehensive Income for the period	1,171.55	3,106.78	1,038.17	6,984.76	3,664.04	5,720.51	2,413.26	4,886.64	10,576.87	10,124.74	3,190.06	5,543.65	8,733.71
XII	Profit/(Loss) attributable to:	-	-	-	-	-	-	2,583.62	4,145.63	10,561.40	7,310.08	2,974.59	2,903.94	5,878.53
	i. Owners of the Company	-	-	-	-	-	-	139.25	20.90	226.15	2,928.19	197.90	2,790.05	2,987.96
	ii. Non-controlling interests	-	-	-	-	-	-	-335.05	824.69	-164.91	-123.85	-53.17	-76.68	-129.85
XIII	Other Comprehensive Income attributable to:	-	-	-	-	-	-	25.44	-104.58	-45.77	10.32	70.73	-73.66	-2.93
	i. Owners of the Company	-	-	-	-	-	-	-	-	-	-	-	-	-
	ii. Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-	-
XIV	Total Comprehensive Income attributable to:	-	-	-	-	-	-	2,248.57	4,970.31	10,396.49	7,186.23	2,921.42	2,827.26	5,748.68
	i. Owners of the Company	-	-	-	-	-	-	164.69	-83.67	180.38	2,938.51	268.63	2,716.39	2,985.03
	ii. Non-controlling interests	-	-	-	-	-	-	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47
XV	Paid up equity share capital (Face Value - Re. 1/- each.)	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47
XVI	Earnings Per Share Basic & Diluted (Not annualised)	1.13	3.01	1.01	6.77	3.56	5.53	2.50	4.02	10.24	7.09	2.88	2.82	5.70



**Notes:**

- 1 The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 29, 2019. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The Statutory Auditors of the company have carried out a Limited Review of the above results.
- 2 The Ministry of Corporate Affairs (MCA), on 28th March, 2018, notified Ind AS 115 "Revenue from Contracts with Customers" as part of the Companies (Indian Accounting Standards) Amendment Rules, 2018 and the same is effective for accounting periods beginning on or after 1st April, 2018. The adoption of this standard did not have any material impact to the financial statements of the Company.
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- 4 During the quarter ended March 31, 2018 a material stepdown subsidiary namely Bliss GVS Healthcare Limited, Nairobi was disinvested and the analysis of revenue, expenses and profit & loss of discontinuing operations has been disclosed in consolidated results for the year ended March 31, 2018 as per para 33(b) of Ind AS 105 'Non-Current Assets held for Sale and Discontinuing Operations'. Accordingly, Revenue from operations and expenses for the quarter and the nine months ended December 31, 2018 is not comparable with the quarter and nine months ended December 31, 2017.
- 5 Other income includes foreign exchange loss of Rs.605.92Lakhs in standalone and consolidated financial result for the quarter ended December 31, 2018.
- 6 The figures for the quarter ended December 31, 2018 are the balancing figures between unaudited figures in respect of the nine months ended December 31,2018 and the year to date published result for the half year ended September 30,2018 .
- 7 Previous year figures have been regrouped/reclassified wherever necessary.

Place : Mumbai  
Date : January 29, 2019



**For BLISS GVS PHARMA LIMITED**



*S. N. Kamath*  
S. N Kamath  
Managing Director  
Din No : 140593



# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

The Board of Directors,  
Bliss GVS Pharma Limited,  
102, Hyde Park,  
Saki Vihar Road,  
Andheri (East),  
Mumbai -400 072.

Dear Sirs,

## LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of '**Bliss GVS Pharma Limited**' ('the Company') for the quarter and nine months ended December 31, 2018, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement is the responsibility of the Company's Management and prepared in accordance with applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013, read with relevant rules and has been approved by the Board of Directors at its meeting held on January 29, 2019. Our responsibility is to issue a report on these consolidated financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We did not review the financial statements of 8 subsidiaries included in the statement, whose financial results reflect the Group's share for the quarter and nine months ended December 31, 2018 for the under mentioned items. These financial statements and other financial information have been reviewed by other auditors whose reports have been furnished to us by the management, and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and to the extent, they have been derived from such financial statements is based on the report of such other auditors.

(In Lakhs)

Particulars	Quarter Ended December 31, 2018	Nine Months Ended December 31, 2018
Total Revenue	12,525.20	33,579.67
Profit After Tax	1,552.80	3,807.67

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

5. Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited Consolidated Financial Results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. In our opinion and to the best of our information and according to the explanations given to us the Statement include financial results of the following subsidiaries included in the consolidation:

**Incorporated in India:**

1. Kremoint Pharma Limited
  - 1.1. Eipii Exports Private Limited
  - 1.2. Eco Rich Cosmetics Private Limited

**Incorporated outside India:**

2. Bliss GVS International Pte. Ltd.
  - 2.1. Greenlife Bliss Healthcare Limited
3. Bliss GVS Clinic Healthcare Pte. Ltd.
4. Asterisk Lifesciences Limited (UK)
  - 4.1. Asterisk Lifesciences (GH) Limited

**For KALYANIWALLA AND MISTRY LLP  
CHARTERED ACCOUNTANTS  
Firm Registration No. 104607W/W100166**



**Sai Venkata Ramana Damarla  
PARTNER  
Membership No. 107017  
Mumbai, January 29, 2019.**

# KALYANIWALLA & MISTRY LLP

C H A R T E R E D   A C C O U N T A N T S

---

The Board of Directors,  
Bliss GVS Pharma Limited,  
102, Hyde Park,  
Saki Vihar Road,  
Andheri (East),  
Mumbai 400 072.

Dear Sirs,

## LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of '**Bliss GVS Pharma Limited**' ('the Company') for the quarter and nine months ended December 31, 2018, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement is the responsibility of the Company's Management and prepared in accordance with applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013, read with relevant rules has been approved by the Board of Directors at its meeting held on January 29, 2019. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone Financial Results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200    FAX : (91) (22) 6158 6275

5. We draw attention to our reliance on management representation, in respect of the realisability of the Company's investment in, loans given and interest accrued to two of its subsidiaries aggregating Rs. 4,098.68 Lakhs.

Our opinion is not modified in respect of this matter.

**For KALYANIWALLA & MISTRY LLP  
CHARTERED ACCOUNTANTS  
Firm Registration No. 104607W/W100166**



**Sai Venkata Ramana Damarla  
PARTNER  
Membership No. 107017  
Mumbai, January 29, 2019.**